Back Clinic Treatments. There are various treatments for all types of injuries and conditions here at Injury Medical & Chiropractic Clinic. The main goal is to correct any misalignments in the spine through manual manipulation and placing misaligned vertebrae back in their proper place. Patients will be given a series of treatments, which are based on the diagnosis. This can include spinal manipulation, as well as other supportive treatments. And as chiropractic treatment has developed, so have its methods and techniques.
Why do chiropractors use one method/technique over another?
A common method of spinal adjustment is the toggle drop method. With this method, a chiropractor crosses their hands and pressed down firmly on an area of the spine. They will then adjust the area with a quick and precise thrust. This method has been used for years and is often used to help increase a patient’s mobility.
Another popular method takes place on a special drop table. The table has different sections, which can be moved up or down based on the body’s position. Patients lie face down on their back or side while the chiropractor applies quick thrusts throughout the spinal area as the table section drops. Many prefer this table adjustment, as this method is lighter and does not include twisting motions used in other methods.
Chiropractors also use specialized tools to assist in their adjustments, i.e., the activator. A chiropractor uses this spring-loaded tool to perform the adjustment/s instead of their hands. Many consider the activator method to be the most gentle of all.
Whichever adjustment method a chiropractor uses, they all offer great benefits to the spine and overall health and wellness. If there is a certain method that is preferred, talk to a chiropractor about it. If they do not perform a certain technique, they may recommend a colleague that does.
Curcumin is the main active ingredient found in turmeric, a bright yellow aromatic powder obtained from the rhizome of a plant in the ginger family commonly utilized for flavoring and coloring in a variety of Asian cuisines, as well as a very strong antioxidant which additionally has powerful anti-inflammatory effects. While turmeric has been consumed for generations due to its medicinal properties, it’s curcumin content is actually not that high. Therefore, if you want to experience its full benefits, it may be best to take a supplement that contains significant amounts of curcumin, or better yet, a supplement specially formulated to bring out the benefits of this naturally occurring chemical compound.
Curcumin is ultimately found in turmeric, the key ingredient in curry, and as a powerful antioxidant that offers numerous health benefits, curcumin helps support joint health and cardiovascular function, and it helps maintain a normal inflammatory reaction in the human body. Individuals throughout Asia have benefited from the healthful effects of curcumin for centuries.�Whether taken as a nutritional supplement or from meals, however, curcumin is usually poorly absorbed into the bloodstream.
Fortunately, global experts in botanical extract technologies have uncovered the key to curcumin absorption: phytosome technology. Meriva curcumin phytosome is an exceptional curcumin extract that’s significantly better absorbed than other curcumin extracts. Curcumin nutrients which have previously been remarkable in “test tube” experiments are extremely poorly absorbed when taken orally by people. The product Curcumin Phytosome comprising Meriva� unites curcumin with another bioactive nutrient, thereby dramatically improving its absorption and releasing its overall health and wellness potential.�Meriva is a unique, patented, time-release curcumin product.
Meriva Product Overview
Phytosomes are plant extracts bound to phosphatidylcholine, or PC, an important component of individual cells. The human body can create PC, or phosphatidylcholine, but it can even be obtained from food and/or supplements. When taken orally, PC is very well absorbed.�PC is a significant building block for membranes, the most metabolically dynamic zones of our cells. PC most likely transfers the curcumins in the bloodstream until they arrive in cell membranes. Researchers found a way to attach a curcumin extract to PC for superior absorption, leading to Meriva.�Curcumin phytosome is a curcumin molecule bonded to a molecule of PC. Unlike curcumin alone, PC is excellently absorbed orally.
When consumers utilize Meriva curcumin phytosome, the body absorbs the PC as well as the attached curcumin, leading to more curcumin reaching the cells which can benefit more from it. After the curcumin phytosomes are accepted as a dietary supplement, PC protects its connected curcumin and economically transports it across the intestinal lining and into the circulating blood. Curcumins at phytosomes are over 29 times better absorbed than curcumin alone. PC itself has proven benefits for the liver, intestines, and lungs, and its existence in the Meriva curcumin phytosome amplifies the benefits available from the curcumin alone.
Dr. Alex Jimenez’s Insight
Turmeric contains four major curcuminoids: curcumin, demethoxycurcumin, bisdemethoxycurcumin and cyclocurcumin. These chemical compounds have been demonstrated to have tremendous benefits, which is why turmeric has been a fundamental addition in Asian cooking. However, curcumin, as well as all the other curcuminoids, are poorly absorbed by the human body when taken orally. Researchers developed Meriva curcumin phytosome, a curcumin compound which is bonded to the molecule phosphatidylcholine, or PC, which promotes the proper absorption of curcumin. Meriva curcumin phytosome can provide a variety of health benefits, including vision and eye health, joint health and even prostrate benefits, among other medicinal properties.
Meriva Curcumin Phytosome Research
Curcumin phytosome with Meriva� is a powerful antioxidant which protects cells and tissues by fighting free radicals. It’s also known to support healthy joint function, eye health and small vessel circulatory health. The curcumin is extracted from turmeric and provides a curcumin complex including, curcumin, bisdemethoxy curcumin and demethoxy curcumin. Meriva� curcumin phytosome is made utilizing the patented Phytosome� technology that enhances the absorption of those curcumins. Comprehensive research over the previous quarter of a century suggests that curcumin helps counter toxins, in addition to influencing cell survival through other means.
Although curcumins are poorly absorbed, Phytosome� technology helps improve bioavailability. The technology evolves every curcumin molecule with one or more atoms of the nutrient phosphatidylcholine, or PC, to create molecular complexes called phytosomes. Curcumin molecules at the Meriva� phytosome complexes are more stable against breakdown and combine far better into water in order for them to be better absorbed when taken orally. The PC molecules in the phytosomes serve as a “delivery vehicle” or even “chaperone”, which not only chemically protects the curcumin molecules but also markedly increases their absorption. A human absorption research discovered that the curcumins were absorbed when taken as Meriva� curcumin phytosomes, in comparison to their basic molecular forms.
The numerous beneficial effects attributed to turmeric root are linked to the antioxidant properties of the curcumins it contains. This antioxidant activity can neutralize free radicals which threaten the integrity of mobile structures. Free radicals may lead to “oxidative stress,” a process that can activate cell damage. In addition, oxidative stress is considered to play a role in the development of a variety of diseases. Because curcumins are poorly absorbed when taken orally, this can tremendously restrict their biological actions. The Phytosome� technology used with Meriva� curcumin phytosome creates phytosome complexes which are proven to be absorbed better.
A 2007 study published in the journal, Cancer Chemotherapy and Pharmacology, revealed Meriva’s exceptional bioavailability in contrast to ordinary curcumin. Liver levels of curcumin were also higher with Meriva supplementation. A recent human research study also demonstrated that Meriva curcumin phytosome has 29-times higher bioavailability. Meriva supplementation also resulted in higher plasma concentrations of curcumin from a much smaller dose compared to ordinary curcumin. In a recent eight-month human trial, Meriva was shown to encourage a healthy inflammatory reaction. People experienced improvements in clinical and biochemical end-points associated with joint health.
Several studies have shown curcumin’s hepatoprotective effects, causing researchers to suggest its use in protecting the liver from exogenous insults due to environmental toxins. Curcumin also has the capacity to increase both the circulation and solubility of bile. Curcumin’s hepatoprotective effects are due in part to lead free-radical scavenging; however, curcumin also enhances the body’s natural antioxidant system, which raises glutathione levels, thus aiding in hepatic detoxification and inhibiting nitrosamine formation. Furthermore, research studies have demonstrated several other health benefits of Meriva curcumin phytosome, including its support in joint health, eye health, vision and circulation, as well as several prostrate benefits, among others.
Supports Joint Health – Two Clinical Trials
In two double-blind trials with subjects having knee problems, Meriva, taken at about 1,000 mg/day, enhanced treadmill walk space by 345 percent after eight months. It improved joint pain, stiffness, swelling and joint work. Intakes of over-the-counter medications fell 63 percent and their adverse effects dropped by 67 percent. The subjects’ medical prices fell 45 percent after 8 months. C-Reactive Protein, or CRP, levels were reduced into a more healthy variety. After eight months, the Karnofsky Scale of well-being moved into “able to perform ordinary activity.”
Supports Eye Health, Vision, Circulation – Three Clinical Trials
One frequent eye problem is a really persistent redness that keeps coming back even when it is cleared. At a clinical trial, 106 patients obtained Meriva, taken at about 1,200 mg/day, for a single year. There were 86 percent fewer returns of this reddening, and in 82 percent of these patients, approximately 87 from 106, it didn’t return at all. In another study, Meriva, taken at about 1,000 mg/day, improved retinal blood circulation, retinal swelling, and eyesight. In only four weeks, visual sharpness improved from an initial average of 20/122-155 to 20/32-78. Meriva also improved circulation elsewhere in the body. In areas with foot blood circulation issues, it substantially reduced immunity, increased oxygen consumption, and enhanced nerve control over the capillary networks. The subjects’ Karnofsky Score of well-being improved, from “normal activity, with effort” into “normal activity.”
Breakthrough Prostate Benefits with Meriva
In a clinical trial on middle-aged men with prostate troubles, Meriva, taken at 1,000 mg/day, significantly enhanced: sense of incomplete bladder emptying, urination frequency, flow stop/start, feeble stream, straining and getting up at night, urinary block, and PSA levels. Quality of life and sexual activity were also considerably improved. The Meriva curcumin phytosome breakthrough guarantees that curcumins are effectively delivered to human cells, in functional mix with PC, or phosphatidylcholine. Multiple effective clinical trials have established curcumin phytosome comprising of Meriva� as the “gold standard” one of curcumin supplements.
In conclusion,�Meriva curcumin phytosome is bound to phosphatidylcholine, or PC, for increased absorption and bioavailability, ultimately protecting DNA against damage by free radicals and reactive oxygen species, among providing a variety of other health benefits. With its enhanced absorption through an improved curcumin absorb delivery system, Meriva curcumin phytosome is clinically documented to promote joint health, eye health, vision and circulation, and even has prostrate benefits. The scope of our information is limited to chiropractic as well as to spinal injuries and conditions. To discuss the subject matter, please feel free to ask Dr. Jimenez or contact us at�915-850-0900�.
Curated by Dr. Alex Jimenez
Additional Topics: Back Pain
Back pain is one of the most prevalent causes for disability and missed days at work worldwide. As a matter of fact, back pain has been attributed as the second most common reason for doctor office visits, outnumbered only by upper-respiratory infections. Approximately 80 percent of the population will experience some type of back pain at least once throughout their life. The spine is a complex structure made up of bones, joints, ligaments and muscles, among other soft tissues. Because of this, injuries and/or aggravated conditions, such as herniated discs, can eventually lead to symptoms of back pain. Sports injuries or automobile accident injuries are often the most frequent cause of back pain, however, sometimes the simplest of movements can have painful results. Fortunately, alternative treatment options, such as chiropractic care, can help ease back pain through the use of spinal adjustments and manual manipulations, ultimately improving pain relief.
Biomarkers (short for biological markers) are biological measurements of a biological condition. By definition, a biomarker is “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacological responses to a therapeutic intervention” Biomarkers are the measurements utilized to perform a clinical evaluation like blood pressure or cholesterol level and therefore are used to monitor and forecast health conditions in individuals or across populations so that appropriate treatment options could be proposed. Biomarkers may be used by itself or in combination to assess the health or disease state of an individual.
Variety of Biomarkers
A wide selection of biomarkers are used now. Every biological system, such as the cardiovascular system, metabolic system or the immune system, has its own specific biomarkers. Many of these biomarkers are rather easy to quantify and form part of regular medical examinations. By way of instance, a general health check may include assessment of blood pressure, heart rate, cholesterol, triglycerides and fasting glucose levels. Body dimensions such as weight, body mass index, or BMI, and waist-to-hip ratio are routinely used for assessing conditions like obesity and metabolic disorders, among others. These varieties in biomarkers can ultimately be useful in the diagnosis of a variety of health issues.
Attributes of a Perfect Biomarker
An ideal biomarker has particular characteristics that make it suitable for assessing a particular disease or condition. Ideally, an ideal marker should possess the following features, as it should be:
Safe and simple to measure
Cost effective to follow up
Modifiable with treatment
Consistent across gender and cultural groups
Biomarkers as Health and Disease Predictors
Biomarkers are used to predict significant ailments like diabetes and cardiovascular disease, among others. Each individual biomarker indicates whether there’s a disease or health condition and can be combined to offer a thorough demonstration of how healthy an individual is and whether further diagnosis needs to be made. Biomarkers ultimately serve as health and disease predictors, capable of determining a potential onset of disease or illness, such as that of cancer.
Biomarkers in Cancer Detection and Drug Development
The principles of biomarkers in disease have been applied to the discovery, screening, diagnosis, treatment and monitoring of cancer. Traditionally, anti-cancer drugs and/or medications were agents that eliminated both cancer cells and healthy cells. However, more targeted therapies have now been developed that can be instructed to kill cancer cells only, while sparing healthy cells. The evaluation of a typical biomarker in cancer will help in the development of therapies that may target the biomarker. This can minimize the risk of toxicity and reduce the cost of treatment. In cancer research, genetic studies are valuable because genetic abnormalities so often underlie the evolution of cancer. Certain DNA or RNA markers might therefore help in the treatment and detection of specific cancers. The purpose of the following article, however, is to demonstrate the biomarkers involved in low back pain, disc degeneration and other chronic pain health issues, such as neuropathic pain.
Inflammatory Biomarkers of Low Back Pain and Disc Degeneration: a Review
Abstract
Biomarkers are biological characteristics that can be used to indicate health or disease. This paper reviews studies on biomarkers of low back pain (LBP) in human subjects. LBP is the leading cause of disability, caused by various spine-related disorders, including intervertebral disc degeneration, disc herniation, spinal stenosis, and facet arthritis. The focus of these studies is inflammatory mediators, because inflammation contributes to the pathogenesis of disc degeneration and associated pain mechanisms. Increasingly, studies suggest that the presence of inflammatory mediators can be measured systemically in the blood. These biomarkers may serve as novel tools for directing patient care. Currently, patient response to treatment is unpredictable with a significant rate of recurrence, and, while surgical treatments may provide anatomical correction and pain relief, they are invasive and costly. The review covers studies performed on populations with specific diagnoses and undefined origins of LBP. Since the natural history of LBP is progressive, the temporal nature of studies is categorized by duration of symptomology/disease. Related studies on changes in biomarkers with treatment are also reviewed. Ultimately, diagnostic biomarkers of LBP and spinal degeneration have the potential to shepherd an era of individualized spine medicine for personalized therapeutics in the treatment of LBP.
Biomarkers for Chronic Neuropathic Pain and their Potential Application in Spinal Cord Stimulation: a Review
Abstract
This review was focused on understanding which substances inside the human body increase and decrease with increasing neuropathic pain. We reviewed various studies, and saw correlations between neuropathic pain and components of the immune system (this system defends the body against diseases and infections). Our findings will especially be useful for understanding ways to reduce or eliminate the discomfort, chronic neuropathic pain brings with it. Spinal cord stimulation (SCS) procedure is one of the few fairly efficient remedial treatments for pain. A follow-up study will apply our findings from this review to SCS, in order to understand the mechanism, and further optimize efficaciousness.
Chronic neuropathic pain disorders represent a common long-term disability in the United States, as well as, globally. They affect 1 in 4 Americans. Chronic neuropathic pain treatment has limited success because of poor understanding of the mechanisms that lead to the initiation and maintenance. Additionally, the effectiveness of neuropathic pain management regimens and procedures has been difficult to determine in the past, due to the subjectivity related to pain perception, and a lack of standardized assessment of neuropathic pain. However, one of the most effective management strategies in recent times is spinal cord stimulation (SCS). The main goals of spinal cord stimulation are to improve physical function and quality of life in the patients afflicted with chronic neuropathic pain associated with complex regional pain syndrome (CRPS), failed back syndrome, and other chronic neuropathic pain syndromes [1�2]. Despite limited knowledge of how people benefit from SCS, more than 20,000 stimulators are implanted each year, with more than a half-billion dollars in revenue [3]. While it is generally believed that spinal cord stimulation inhibits pain transmission in the dorsal horn, the exact mechanisms by which SCS relieves neuropathic pain is unknown. Chronic neuropathic pain is caused often by inflammation and/or nerve injury. The advances have shown that inflammation and nerve injury produce changes in the expression of cytokines, neurotransmitters, and structural proteins [4]. It is very likely that there are changes in the body�s serum biomarkers of neuropathic pain before SCS and after SCS. Such a study would contribute greatly to the field of neuromodulation, as objective quantifiers of neuropathic pain control before and after SCS have not yet been investigated. Such definitive data regarding the effectiveness of SCS in relieving neuropathic pain and improving function will be important in future use of SCS.
In preparation for the launching of this study, the authors� goal with this transcript is to provide a review of the literature regarding known biomarkers for chronic neuropathic pain, and then prepare a role for biomarker analysis in the prediction of therapy success in SCS.
Data
The expression of certain genes is altered under chronic pain conditions. This alteration has helped provide an insight into the identification of potential biomarkers [5]. Current advanced research suggests that genetic expression of cytokines, positively or negatively, correlates with the experience of chronic pain. This negative or positive correlation primarily depends on the nature of the cytokine. Cytokines are signaling proteins which mediate the activation, differentiation, and proliferation of immune cells. They can be pro-inflammatory or anti-inflammatory. A misaligned balance between pro-inflammatory and anti-inflammatory cytokines has been common in most of the studies conducted (Table 1). Pro-inflammatory cytokines such as IL-1?, IL-6, IL-2, IL-33, CCL3, CXCL1, CCR5, and TNF-?, have been found to play significant roles in the amplification of chronic pain states. In studies involving discogenic pain, Complete Freund�s adjuvant (CFA)-induced discogenic pain in animal models has been observed to coincide with a sustained up-regulation of the above named cytokines [6]. In a more recent study, chronic constriction injury (CCI)-induced rats (neuropathic pain induction) were shown to have increased serum levels of CCL3 and CCR5. Even more interesting, an intrathecal injection of the anti-inflammatory cytokine, IL-4, and the CCL3-neutralizing antibody, reduced the CCI-induced neuropathic pain, estimated by a plantar test [7]. Other studies have also shown that the selective genetic impairment of the highlighted pro-inflammatory cytokines attenuated nerve-injury induced pain behavior, observed in neuropathic pain models [8]. Particularly, Zarpelon et al. revealed that CCI-induced rats showed reduced mechanical hyperalgesia when the IL-33 receptor gene, IL-33R (ST2), was knocked out, compared to the wild-type mice [9].
On the other hand, one study showed that blood levels of anti-inflammatory cytokines (such as IL-10 and IL-4) of Complex Regional Pain Syndrome (CRPS) patients were lower compared to the control [10]. A recent study also shows a distinction of the significant increases of pro-inflammatory cytokines based on the part of the back affected. There were more significant elevations (p<0.05, student�s t test) of pro-inflammatory cytokines in the plasma of lower back pain patients than in upper back patients, when compared to controls [11]. There has also been a study focusing on the levels of the aforementioned cytokines in patients with painful neuropathy in contrast with painless neuropathy and healthy control subjects. Patients with a painful neuropathy had about double the level of IL-2 expression (p = 0.001), TNF expression (p < 0.0001) and protein levels (p = 0.009) than the controls. The study further indicated there was about double the IL-2 and TNF level expression (p = 0.03; p = 0.001) and protein levels in painful neuropathy (p = 0.04; p = 0.04) than patients with painless neuropathy. On the contrary, levels of mRNA expression of the anti-inflammatory cytokines, IL-10 and IL-4 were considerably lower in patients with painful neuropathy than in patients with painless neuropathy (p =0.001) [12].
Several other studies, focused on the antagonist and agonist effects of some drugs targeting pro-inflammatory and anti-inflammatory cytokines, also have pointed out their significance with pain. Certain known analgesics were seen to reduce the levels of pro-inflammatory cytokines in the studies reviewed. There was a study about (CCI)-induced rats, in which case, this induced injury significantly, elevated the levels of pro-inflammatory cytokines, and decreased the serum levels of anti-inflammatory cytokines. Omeprazole, a known remedy for stomach pain, was observed to reduce the levels of pro-inflammatory cytokines (TNF-?, IL-1?, and IL-6) to normal, compared with the CCI control. It is important to note that this was while curbing the CCI-induced neuropathic pain, measured with the paw withdrawal latency [13]. Zhou et al. also highlighted the significance of certain drugs in determining the correlation between cytokines and neuropathic pain. CCI was again, used to induce neuropathic pain on rat models; and in turn, Paenoflorin, an established analgesic [14] was administered. Once Paenoflorin was introduced, significant decreases in serum levels of pro-inflammatory cytokines of CCI-induced rats (IL-1?, IL-6, TNF-?, and CXCL1) were observed, compared to the CCI-control [15]. The cytokines identified here, are the ones that showed correlation in various studies reviewed.
Even though cytokines are the key chronic pain biomarkers, according to the studies reviewed, there are still other proteins and nucleotides that have been observed to associate with chronic pain disorder. Two studies laid emphasis on regulatory microRNAs (miRNAs), which are small non-coding RNA molecules involved in post-transcriptional gene regulation. miRNAs achieve this by binding to mRNAs and degrading them or repressing their functions. Orlova et al. showed that 60% of CRPS patients in their study showed a significant down-regulation of 18 different miRNAs. The rest of the patients, however, showed variable (contradicting) miRNA levels. miRNA levels show variability, depending on the gene being regulated [5]. Tao et al. revealed that an increased inflammatory stimulation by the cytokine IL-1? in normal and osteoarthritis chondrocytes produced a significant down-regulation of the miRNA, miR-558, and a significant up-regulation of miR-21 in DRG neurons. A connection between IL-1? and miR-21 was attributed to AP-1, which is a transcription factor located in the promoter site of the mRNA, and is activated by IL-1? [4]. siRNAs have the same features as miRNAs, in the sense, that they are regulatory nucleotides. They also show variability, depending on the gene being regulated. SIRT1, a deacetylase, functions in regulating various pathways, including inflammation. It was observed that an intrathecal injection of SRT170, an SIRT1 agonist, reduced serum levels of NF-?B, a transcription factor for pro-inflammatory cytokines, in CCI-induced rat models. When SRT170-siRNA (a regulator of the regulator) was administered before SRT170, there was no agonistic effect [16].
Dr. Alex Jimenez’s Insight
A biomarker is most accurately defined as any measurement which demonstrates an interaction between a biological system and the possibility of a chemical, physical or biological hazard. However, biomarkers are often most commonly associated with medicine. In this setting, these can be utilized to determine the effects a particular treatment may have on a patient as well as for determining the risk a patient may have of developing certain health issues. An example of a diagnostic use of biomarkers includes the measurement of biomarkers in blood to evaluate the severity of a heart attack. In the same manner, blood samples can be analyzed and biomarkers can be measured in the instance of chronic pain.
Discussion
Chronic neuropathic pain affects a tremendous amount of the population. There are few effective therapies. However, outcomes are hard to determine due to the subjective nature of pain. We would like to devise a strategy that would establish objectivity of pain assessment. After review of various studies relating to pain biomarkers, we found that serum levels of pro-inflammatory cytokines and chemokines, such as IL-1?, IL-6, IL-2, IL-33, CCL3, CXCL1, CCR5, and TNF-?, were significantly up-regulated during chronic pain experience. On the other hand, anti-inflammatory cytokines such as IL-10 and IL-4 were found to show significant down-regulation during chronic pain state. Regulatory miRNAs, siRNAs, and deacetylases that coincide with these cytokines, also showed negative correlation, corresponding to the cytokine they were regulating.
The authors would like to apply this knowledge to SCS, a therapy for chronic neuropathic pain, in an attempt to develop a biomarker profile to help predict success. This study will be a prospective study including patients scheduled for SCS. One month before SCS surgery, patients will complete a survey assessing their subjective level of pain on the visual analog scale and subjective level of function. Patients will also have venipuncture performed, and serum will be analyzed for levels of pain biomarkers. After SCS surgery, patients will be followed at 6 more time points: 2 weeks, 1 month, 3 months, 6 months, 1 year, and 2 years. At each time point, the survey will be re-administered and blood work will be repeated. By evaluating patients pre-operatively and post-operatively, we will be able to assess subjective and objective levels of pain, allowing us to analyze trends in pain biomarkers in the context of patient-reported pain measurement. The duration of this study will be 4 years. Each subject will participate in this study for a total period of 25 months, which will allow us to follow these patients for 2 years postoperatively.
Conclusion
The review of various studies relating to inflammation- and/or nerve injury-induced chronic pain disorder led us to hypothesize that the application of the spinal cord stimulation procedure should relatively reduce serum pro-inflammatory cytokines, and relatively increase serum levels of anti-inflammatory cytokines. This should, in turn, help us understand the mechanism of spinal cord stimulation, thereby optimizing the efficaciousness of the procedure, and perhaps allow us to make predictions regarding therapy success. A follow-up prospective study regarding serum biomarker profile in SCS patients is currently being undertaken.
Footnotes
Author Disclosure:The authors declare no conflicts of interest.
Disclosure of Funding:This work was supported by grants from the University of Medicine and Dentistry of New Jersey and the National Institutes of Health, Bethesda, Maryland (grant numbers: NS072206, HL117684, and DA033390).
In conclusion,�diagnostic biomarkers have the potential of leading new personalized therapeutics in the treatment of chronic pain health issues, such as low back pain, disc degeneration and neuropathic pain. Several research studies like the ones above have been established to ultimately help healthcare professionals understand better ways to reduce or eliminate the pain and discomfort associated with these chronic pain problems. Furthermore, biomarkers can be essential diagnostic tools for the evaluation and treatment of a variety of health issues. Information referenced from the National Center for Biotechnology Information (NCBI).�The scope of our information is limited to chiropractic as well as to spinal injuries and conditions. To discuss the subject matter, please feel free to ask Dr. Jimenez or contact us at�915-850-0900�.
Curated by Dr. Alex Jimenez
Additional Topics: Back Pain
Back pain is one of the most prevalent causes for disability and missed days at work worldwide. As a matter of fact, back pain has been attributed as the second most common reason for doctor office visits, outnumbered only by upper-respiratory infections. Approximately 80 percent of the population will experience some type of back pain at least once throughout their life. The spine is a complex structure made up of bones, joints, ligaments and muscles, among other soft tissues. Because of this, injuries and/or aggravated conditions, such as herniated discs, can eventually lead to symptoms of back pain. Sports injuries or automobile accident injuries are often the most frequent cause of back pain, however, sometimes the simplest of movements can have painful results. Fortunately, alternative treatment options, such as chiropractic care, can help ease back pain through the use of spinal adjustments and manual manipulations, ultimately improving pain relief.
2.�Kumar K, Hunter G, Demeria D. Spinal Cord Stimulation in Treatment of Chronic Benign Pain: Challenges in Treatment Planning and Present Status, a 22-year Experience.�Neurosurgery.�2006;58:481�491.�[PubMed]
3.�Vallejo R, Kramer J, Benjamin R. Neuromodulation of the Cervical Spinal Cord in the Treatment of Chronic Intractable Neck and Upper Extremity Pain: A Case Series and Review of the Literature.�Pain Physician.�2007;10:305�311.�[PubMed]
4.�Lutz BM, Bekker A, Tao YX. Non-coding RNAs: New Players in Chronic Pain.�Anesthesiology.�2014 doi: 10.1097/ALN.0000000000000265.�[PMC free article]�[PubMed]�[Cross Ref]
5.�Orlova IA, Alexander GM, Qureshi RA, Sacan A, et al. MicroRNA Modulation in Complex Regional Pain Syndrome.�Journal of Translational Medicine.�2011;9:195.�[PMC free article]�[PubMed]
6.�Jung WW, Kim HS, Shon JR, et al. Intervertebral Disc Degeneration-induced Expression of Pain-Related Molecules: Glial Cell-derived Neurotropic Factor as a Key Factor.�J Neurosurg Anesthesiol.�2011;23:329�334.�[PubMed]
7.�Sun S, Chen D, Lin F, Chen M, Yu H, Hou L, Li C. Role of Interleukin-4, the Chemokine CCL3 and its Receptor CCR5 in Neuropathic Pain.�Mol Immunol.�2016;77:184�192.�[PubMed]
8.�Clark AK, Old EA, Malcangio M. Neuropathic Pain and Cytokines: Current Perspectives.�Journal of Pain Research.�2013;6:803�814.�[PMC free article]�[PubMed]
10.�Parkitny L, McAuley JH, Pietro FD, Stanton TR, O�Connell NE, Marinus J, van Hilten JJ, Moseley GL. Inflammation in Complex Regional Pain Syndrome.�Neurology.�2013;80:106�117.�[PMC free article][PubMed]
11.�Li Y, Liu J, Liu ZZ, Duan DP. Inflammation in Low Back may be detected from the Peripheral Blood: Suggestions for Biomarker.�Bioscience Reports.�2016 doi: 10.1042/BSR20160187.�[PMC free article][PubMed]�[Cross Ref]
12.�Uceyler N, Rogausch JP, Toyka KV, Sommer C. Differential Expression of Cytokines in Painful and Painless Neuropathies.�Neurology.�2007;69:42�49.�[PubMed]
13.�Chanchal SK, Mahajan UB, Siddharth S, Reddy N, Goyal SN, Patil PH, Bommanahalli BP, Kundu CN, Patil CR, Ojha S. In Vivo and In Vitro Protective Effects of Omeprazole against Neuropathic Pain.�Sci Rep.�2016;6:30007.�[PMC free article]�[PubMed]
14.�Yin D, Liu YY, Wang TX, Hu ZZ, Qu WM, Chen JF, Cheng NN, Huang ZL. Paeoniflorin exerts analgesic and hypnotic effects via adenosine A1 receptors in a mouse neuropathic pain model.�Psychopharmacology (Berl)�2016 Jan;233(2):281�93.�[PubMed]
15.�Zhou J, Wang L, Wang J, Wang C, Yang Z, Wang C, Zhu Y, Zhang J. Evid Based Complement.�Alternat Med.�2016;2016:8082753.�[PMC free article]�[PubMed]
16.�Lv C, Hu HY, Zhao L, Zheng H, Luo XZ, Zhang J. Intrathecal SRT1720, a SIRT1 agonist, exerts anti-hyperalgesic and anti-inflammatory effects on chronic constriction injury-induced neuropathic pain in rats.�Int J Clin Exp Med.�2015;8(5):7152�7159.�[PMC free article]�[PubMed]
17.�Kraychete DC, et al. Serum Cytokine Levels in Patients with Chronic Low Back Pain due to Herniated Disc: Analytical Cross-Sectional Study.�Sao Paulo Med J.�2010;128(5):259�292.�[PubMed]
18.�Bazzichi L, et al. Cytokine Patterns in Fibromyalgia and Their Correlation with Clinical Manifestations.�Clinical and Experimental Rheumatology.�2007;25:225�230.�[PubMed]
19.�Iannuccelli C, et al. Pathophysiology of Fibromyalgia: A Comparison with the Tension-Type Headache, a Localized Pain Syndrome.�Ann NY Acad Sci.�2010;1193:78�83.�[PubMed]
20.�Backonja MM, Coe CL, Muller DA, Schell K. Altered Cytokine Levels in the Blood and Cerebrospinal Fluid of Chronic Pain Patients.�Journal of Neuroimmunology.�2008;195:157�163.�[PubMed]
21.�Empl M1, Renaud S, Erne B, Fuhr P, Straube A, Schaeren-Wiemers N, Steck AJ. TNF-Alpha Expression in Painful and Non-painful Neuropathies.�Neurology.�2001;56(10):1371�7.�[PubMed]
22.�Della Vedova C, et al. Peripheral Interleukin-1? Levels are elevated in Chronic Tension-Type Headache Patients.�Pain Res Manag.�2013;18(6):301�306.�[PMC free article]�[PubMed]
23.�Ko�er A, et al. Interleukin-6 Levels in Tension Headache Patients.�Clin J Pain.�2010;26:690�693.[PubMed]
24.�Bekker A, Haile M, Kline R, Didehvar S, Babu R, Martiniuk F, Urban M. The effect of intraoperative infusion of dexmedetomidine on the quality of recovery after major spinal surgery.�J Neurosurg Anesthesiol.�2013;25(1):16�24.�[PMC free article]�[PubMed]
25.�Dominques RB, Duarte H, Rocha NP, Teixeira AL. Increased Serum Levels of Interleukin-8 in Patients with Tension-Type Headache.�Cephalagia.�2014;0(0):1�6.
Arthritis pain is a complex phenomenon involving intricate neurophysiological processing at all levels of the pain pathway. The treatment options available to alleviate joint pain are fairly limited, and most arthritis patients report only modest pain relief with current treatments. A better understanding of the neural mechanisms responsible for musculoskeletal pain and identifying new targets will help develop future pharmacological therapies. This article reviews some of the latest research into factors that contribute to joint pain and covers areas such as cannabinoids, proteinase-activated receptors, sodium channels, cytokines, and transient receptor potential channels. The emerging hypothesis that osteoarthritis may have a neuropathic component is also discussed.
Introduction
The world health organization ranks musculoskeletal disorders as the most frequent cause of disability in the modern world, affecting one in three adults [1]. Even more alarming is that the prevalence of these diseases is rising while our knowledge of their underlying causes is fairly rudimentary.
Fig. 1 A schematic illustrating some of the targets known to modulate joint pain. Neuromodulators can be released from nerve terminals as well as mast cells and macrophages to alter afferent mechanosensitivity. Endovanilloids, acid, and noxious heat can activate transient receptor potential vanilloid type 1 (TRPV1) ion channels leading to the release of algogenic substance P (SP), which subsequently binds to neurokinin-1 (NK1) receptors. Proteases can cleave and stimulate protease-activated receptors (PARs). Thus far, PAR2and PAR4have been shown to sensitize joint primary afferents. The endocannabinoid anandamide (AE) is produced on demand and synthesized from N-arachidonoyl phosphatidylethanolamine (NAPE) under the enzymatic action of phospholipases. A portion of AE then binds to cannabinoid-1 (CB1) receptors leading to neuronal desensitization. Unbound AE is rapidly taken up by an anandamide membrane transporter (AMT)before being broken down by a fatty acid amide hydrolase (FAAH)into ethanolamine (Et) and arachidonic acid (AA). The cytokines tumor necrosis factor-?(TNF-?), interleukin-6 (IL-6) and interleukin1-beta (IL-1?) Can bind to their respective receptors to enhance pain transmission. Finally, tetrodotoxin (TTX)-resistant sodium channels (Nav1.8) are involved in neuronal sensitization.
Patients yearn for their chronic pain to disappear; however, currently prescribed analgesics are largely ineffective and are accompanied by a wide range of unwanted side effects. As such, millions of people worldwide are suffering from the debilitating effects of joint pain, for which there is no satisfactory treatment [2].
More than 100 different forms of arthritis have osteoarthritis (OA) being the most common. OA is a progressively degenerative joint disease that causes chronic pain and loss of function. Commonly, OA is the inability of the joint to repair damage effectively in response to excessive forces being placed on it. The biological and psychosocial factors that comprise chronic OA pain are not well understood, although ongoing research unravels the complex nature of disease symptoms [2]. Current therapeutics, such as non-steroidal anti-inflammatory drugs (NSAIDs), provide some symptomatic relief, reducing the pain for short periods of time, but do not alleviate pain across the patient’s lifespan. Furthermore, high-dose NSAIDs cannot be taken repeatedly over many years, as this can lead to renal toxicity and gastrointestinal bleeding.
Traditionally, arthritis research has focused largely on the articular cartilage as a primary target for the therapeutic development of novel OA drugs for disease modification. This chondrogenic focus has shed new light on the intricate biochemical and biomechanical factors that influence chondrocyte behavior in diseased joints. However, as the articular cartilage is aneural and avascular, this tissue is unlikely to be the source of OA pain. This fact, coupled with the findings that there is no correlation between the damage of articular cartilage and pain in OA patients [3,4] or preclinical models of OA [5], has caused a shift in focus to develop drugs for effective pain control. This article will review the latest findings in joint pain research and highlight some of the emerging targets that may be the future of arthritis pain management (summarized in Fig. 1)
Cytokines
The actions of various cytokines in joint neurophysiology studies have featured quite prominently recently. Interleukin-6 (IL-6), for example, is a cytokine that typically binds to the membrane-bound IL-6 receptor (IL-6R). IL-6 can also signal by binding with a soluble IL-6R (SIL-6R) to produce an IL-6/sIL-6R complex. This IL-6/sIL-6R complex subsequent lybinds to a transmembrane glycoprotein subunit 130(gp130), thereby allowing IL-6 to signal in cells that do not constitutively express membrane-bound IL-6R [25,26]. IL-6 and SIL-6R are key players in systemic inflammation and arthritis, as upregulation of both has been found in RA patients’ serum and synovial fluid [27,29]. Recently, Vazquez et al.observed that co-administration of IL-6/sIL-6R into rat knees caused inflammation-evoked pain, as revealed by an increase in the response of spinal dorsal horn neurons to mechanical stimulation of the knee and other parts of the hindlimb [30]. Spinal neuron hyperexcitability was also seen when IL-6/sIL-6R was applied locally to the spinal cord. Spinal application of soluble gp130 (which would mop up IL-6/sIL-6R complexes, thereby reducing trans-signaling) inhibited IL-6/sIL-6R-induced central sensitization. However, acute application of soluble gp130 alone did not reduce the neuronal responses to already established joint inflammation.
The transient receptor potential (TRP) channels are non-selective cation channels that act as integrators of various physiological and pathophysiological processes. In addition to thermosensation, chemosensation, and mechanosensation, TRP channels are involved in the modulation of pain and inflammation. For example, TRP vanilloid-1 (TRPV1) ion channels have been shown to contribute to joint inflammatory pain as thermal hyperalgesia was not evocable in TRPV1 mono arthritic mice [31]. Similarly, TRP ankyrin-1 (TRPA1)ion channels are involved in arthritic mechano hypersensitivity as blockade of the receptor with selective antagonists attenuated mechanical pain in the Freunds complete adjuvant model inflammation [32,33]. Further evidence thatTRPV1 may be involved in the neurotransmission of OA pain comes from studies in which neuronal TRPV1 expression is elevated in the sodium monoiodoacetate model of OA [34]. In addition, systemic administration of the TRPV1 antagonist A-889425 reduced the evoked and spontaneous activity of spinal-wide dynamic range and nociception-specific neurons in the monoiodoacetate model [35]. These data suggest that endovanilloids could be involved in central sensitization processes associated with OA pain.
There are currently known to be at least four polymorphisms in the gene that encodes TRPV1, leading to an alteration in the structure of the ion channel and impaired function. One particular polymorphism (rs8065080) alters the sensitivity of TRPV1 to capsaicin, and individuals carrying this polymorphism are less sensitive to thermal hyperalgesia [36]. A recent study examined whether OA patients with the rs8065080 polymorphism experienced altered pain perception based on this genetic anomaly. The research team found that patients with asymptomatic knee OA were more likely to carry the rs8065080 gene than patients with painful joints [37]. This observation indicates that OA patients with normal functioning; TRPV1 channels have an increased risk of joint pain and re-affirms the potential involvement of TRPV1 in OA pain perception.
Conclusion
While the hurdle of treating arthritis pain effectively remains, great leaps are being made in our understanding of the neurophysiological processes responsible for the generation of joint pain. New targets are being discovered continually, while the mechanisms behind known pathways are being further defined and refined. Targeting one specific receptor or ion channel is unlikely to be the solution to normalizing joint pain, but rather a polypharmacy approach is indicated in which various mediators are used in combination during specific phases of the disease. Unraveling the functional circuitry at each level of the pain pathway will also improve our knowledge of how joint pain is generated. For example, identifying the peripheral mediators of joint pain will allow us to control nociception within the joint and likely avoid the central side effects of systemically administered pharmacotherapeutics.
FACETOGENIC PAIN
FACET SYNDROME & FACETOGENIC PAIN
Facet syndrome is an articular disorder related to the lumbar facet joints and their innervations and produces both local and radiating facetogenic pain.
Excessive rotation, extension, or flexion of the spine (repeated overuse) can result in degenerative changes to the joint’s cartilage. In addition, itt may involve degenerative changes to other structures, including the intervertebral disc.
CERVICAL FACET SYNDROME & FACETOGENIC PAIN
Axial neck pain (rarely radiating past the shoulders), most common unilaterally.
Pain with and/or limitation of extension and rotation
Tenderness upon palpation
Radiating facetogenic pain locally or into the shoulders or upper back, and rarely radiate in the front or down an arm or into the fingers as a herniated disc might.
LUMBAR FACET SYNDROME & FACETOGENIC PAIN
Pain or tenderness in the lower back.
Local tenderness/stiffness alongside the spine in the lower back.
Pain, stiffness, or difficulty with certain movements (such as standing up straight or getting up from a chair.
Pain upon hyperextension
Referred pain from upper lumbar facet joints can extend into the flank, hip, and upper lateral thigh.
Referred pain from lower lumbar facet joints can penetrate deep into the thigh, laterally and/or posteriorly.
L4-L5 and L5-S1 facet joints can refer to pain extending into the distal lateral leg, and in rare instances, to the foot
EVIDENCE-BASED MEDICINE
Evidence-based Interventional Pain Medicine according to Clinical Diagnoses
12. Pain Originating from the Lumbar Facet Joints
Abstract
Although the existence of a facet syndrome had long been questioned, it is now generally accepted as a clinical entity. Depending on the diagnostic criteria, the zygapophysial joints account for between 5% and 15% of cases of chronic, axial low back pain. Most commonly, facetogenic pain results from repetitive stress and/or cumulative low-level trauma, leading to inflammation and stretching of the joint capsule. The most frequent complaint is axial low back pain with referred pain perceived in the flank, hip, and thigh. No physical examination findings are pathognomonic for diagnosis. The strongest indicator for lumbar facetogenic pain is pain reduction after anesthetic blocks of the rami mediales (medial branches) of the rami dorsales that innervate the facet joints. Because false-positive and, possibly, false-negative results may occur, results must be interpreted carefully. In patients with injection-confirmed zygapophysial joint pain, procedural interventions can be undertaken in the context of a multidisciplinary, multimodal treatment regimen that includes pharmacotherapy, physical therapy, and regular exercise, and, if indicated, psychotherapy. Currently, the gold standard for treating facetogenic pain is radiofrequency treatment (1 B+). The evidence supporting intra-articular corticosteroids is limited; hence, this should be reserved for those who do not respond to radiofrequency treatment (2 B1).
Facetogenic Pain emanating from the lumbar facet joints is a common cause of low back pain in the adult population. Goldthwaite was the first to describe the syndrome in 1911, and Ghormley is generally credited with coining the term �facet syndrome� in 1933. Facetogenic pain is defined as pain that arises from any structure that is part of the facet joints, including the fibrous capsule, synovial membrane, hyaline cartilage, and bone.35
More commonly, it is the result of repetitive stress and/or cumulative low-level trauma. This leads to inflammation, which can cause the facet joint to be filled with fluid and swell, resulting in stretching of the joint capsule and subsequent pain generation.27 Inflammatory changes around the facet joint can also irritate the spinal nerve via foraminal narrowing, resulting in sciatica. In addition, Igarashi et al.28 found that inflammatory cytokines released through the ventral joint capsule in patients with zygapophysial joint degeneration may be partially responsible for the neuropathic symptoms in individuals with spinal stenosis. Predisposing factors for zygapophysial joint pain include spondylolisthesis/lysis, degenerative disc disease, and advanced age.5
I.C ADDITIONAL TESTS
The prevalence rate of pathological changes in the facet joints on radiological examination depends on the mean age of the subjects, the radiological technique used, and the definition of abnormality. Degenerative facet joints can be best visualized via computed tomography (CT) examination.49
NEUROPATHIC PAIN
Pain initiated or caused by a primary lesion or dysfunction in the somatosensory nervous system.
Neuropathic pain is usually chronic, difficult to treat, and often resistant to standard analgesic management.
Abstract
Neuropathic pain is caused by a lesion or disease of the somatosensory system, including peripheral fibers (A?, A? and C fibers) and central neurons, and affects 7-10% of the general population. Multiple causes of neuropathic pain have been described. Its incidence is likely to increase due to the aging global population, increased diabetes mellitus, and improved survival from cancer after chemotherapy. Indeed, imbalances between excitatory and inhibitory somatosensory signaling, alterations in ion channels, and variability in how pain messages are modulated in the central nervous system all have been implicated in neuropathic pain. Furthermore, the burden of chronic neuropathic pain seems to be related to the complexity of neuropathic symptoms, poor outcomes, and difficult treatment decisions. Importantly, quality of life is impaired in patients with neuropathic pain due to increased drug prescriptions and visits to health care providers and the morbidity from the pain itself and the inciting disease. Despite challenges, progress in understanding the pathophysiology of neuropathic pain is spurring the development of new diagnostic procedures and personalized interventions, which emphasize the need for a multidisciplinary approach to the management of neuropathic pain.
PATHOGENESIS OF NEUROPATHIC PAIN
PERIPHERAL MECHANISMS
After a peripheral nerve lesion, neurons become more sensitive and develop abnormal excitability and elevated sensitivity to stimulation.
This is known as…Peripheral Sensitization!
CENTRAL MECHANISMS
As a consequence of ongoing spontaneous activity in the periphery, neurons develop an increased background activity, enlarged receptive fields, and increased responses to afferent impulses, including normal tactile stimuli. This is known as…Central Sensitization!
Chronic neuropathic pain is more frequent in women (8% versus 5.7% in men) and in patients >50 years of age (8.9% versus 5.6% in those <49 years of age), and most commonly affects the lower back and lower limbs, neck and upper limbs24. Lumbar and cervical painful radiculopathies are probably the most frequent cause of chronic neuropathic pain. Consistent with these data, a survey of >12,000 patients with chronic pain with both nociceptive and neuropathic pain types, referred to pain specialists in Germany, revealed that 40% of all patients experienced at least some characteristics of neuropathic pain (such as burning sensations, numbness, and tingling); patients with chronic back pain and radiculopathy were particularly affected25.
The contribution of clinical neurophysiology to the comprehension of the tension-type headache mechanisms.
Abstract
So far, clinical neurophysiological studies on tension-type headache (TTH) have been conducted with two main purposes: (1) to establish whether some neurophysiological parameters may act as markers of TTH, and (2) to investigate the physiopathology of TTH. Regarding the first point, the present results are disappointing since some abnormalities found in TTH patients may also be frequently observed in migraineurs. On the other hand, clinical neurophysiology has played an important role in the debate about the pathogenesis of TTH. Studies on the exteroceptive suppression of the temporalis muscle contraction have detected a dysfunction of the brainstem excitability and suprasegmental control. A similar conclusion has been reached using trigeminocervical reflexes, whose abnormalities in TTH have suggested a reduced inhibitory activity of brainstem interneurons, reflecting abnormal endogenous pain control mechanisms. Interestingly, the neural excitability abnormality in TTH seems to be a generalized phenomenon, not limited to the cranial districts. Defective DNIC-like mechanisms have indeed been evidenced also in somatic districts by nociceptive flexion reflex studies. Unfortunately, most neurophysiological studies on TTH are marred by serious methodological flaws, which should be avoided in future research to clarify the TTH mechanisms better.
References:
Neurophysiology of arthritis pain. McDougall JJ1 Linton P.
Pain originating from the lumbar facet joints. van Kleef M1,Vanelderen P,Cohen SP,Lataster A,Van Zundert J,Mekhail N.
Neuropathic painLuana Colloca,1Taylor Ludman,1Didier Bouhassira,2Ralf Baron,3Anthony H. Dickenson,4David Yarnitsky,5Roy Freeman,6Andrea Truini,7Nadine Attal, Nanna B. Finnerup,9Christopher Eccleston,10,11Eija Kalso,12David L. Bennett,13Robert H. Dworkin,14and Srinivasa N. Raja15
The contribution of clinical neurophysiology to the comprehension of the tension-type headache mechanisms. Rossi P1, Vollono C, Valeriani M, Sandrini G.
Heel Spur: Blanca, born and raised in El Paso, TX, has been suffering from heel spurs for about two years. As a registered nurse, her symptoms significantly affected her ability to work and her overall quality of life. Determined to improve her health, Blanca considered chiropractic care. Once she started treatment with Dr. Alex Jimenez, however, Blanca experienced tremendous relief from her heel spurs, almost instantly. Blanca highly recommends chiropractic care with Dr. Alex Jimenez as the non-surgical choice for treatment of heel spurs.
Chiropractic Heel Spur Treatment
A heel spur is a calcium residue resulting in a bony protrusion on the bottom of the heel bone. Although heel spurs are often painless, they can lead to heel pain. They are often associated with plantar fasciitis, a painful inflammation of the fibrous band of connective tissue (plantar fascia) that runs across the bottom of the foot and also connects the heel bone to the ball of the foot. Heel spurs are usually caused by strains on foot muscles and ligaments, stretching of the plantar fascia, and repeated tearing of the membrane which covers the heel bone. Heel spurs are particularly common among athletes.
We are blessed to present to you�El Paso�s Premier Wellness & Injury Care Clinic.
As El Paso�s Chiropractic Rehabilitation Clinic & Integrated Medicine Center,�we passionately are focused treating patients after frustrating injuries and chronic pain syndromes. We focus on improving your ability through flexibility, mobility and agility programs tailored for all age groups and disabilities.
If you have enjoyed this video and/or we have helped you in any way please feel free to subscribe and share us.
Truide Torres recibi� atenci�n quiropr�ctica con la Dra. Alex Jim�nez debido al dolor que experiment� a lo largo de su espalda baja, caderas y piernas. Ella fue diagnosticada con dolor en el nervio ci�tico, com�nmente conocida como ci�tica. La ci�tica puede ocurrir cuando los discos intervertebrales, que se encuentran a lo largo de la columna vertebral, comprimen o afectan el nervio ci�tico en la parte inferior de la espalda. Truide Torres experiment� un alivio tremendo de sus s�ntomas una vez que recibi� atenci�n quiropr�ctica con la Dra. Alex Jimenez y pudo regresar a sus actividades cotidianas. Truide Torres recomienda altamente la atenci�n quiropr�ctica para el dolor del nervio ci�tico.
Tratamiento de Ci�tica
Los doctores en Quiropr�ctica (DC) regularmente tratan la ci�tica. La ci�tica se caracteriza por un dolor que se origina en la parte inferior de la espalda o las nalgas, que se desplaza hacia una o ambas piernas. El dolor del nervio ci�tico var�a en intensidad y frecuencia. La ci�tica generalmente es provocada por la compresi�n del nervio ci�tico. Los trastornos conocidos por causar ci�tica incluyen subluxaciones de la columna lumbar (cuerpos vertebrales desalineados), discos herniados o abultados (discos deslizados), embarazo y parto, tumores y dolencias no espinales como diabetes, estre�imiento o estar sentado en el bolsillo trasero. El dolor a menudo es sordo, doloroso, agudo, como un diente, alfileres y agujas o similar a las descargas el�ctricas. Otros s�ntomas relacionados con la ci�tica incluyen sensaci�n de ardor, entumecimiento y hormigueo.tor.
Tenemos la bendici�n de presentarle la Cl�nica Premier de bienestar y lesiones de El Paso.
Como Cl�nica de Rehabilitaci�n Quiropr�ctica y Centro de Medicina Integrada de El Paso, nos enfocamos apasionadamente en tratar pacientes despu�s de lesiones frustrantes y s�ndromes de dolor cr�nico. Nos enfocamos en mejorar su capacidad a trav�s de programas de flexibilidad, movilidad y agilidad dise�ados para todos los grupos de edad y discapacidades.
Si ha disfrutado de este video y / o le hemos ayudado de alguna manera, no dude en suscribirse y compartirnos.
Doctor of Chiropractic Near Me: Mike Melgoza is an active individual who engages in a variety of strenuous physical activities on a regular basis, as a result, however, he began to experience chronic pain symptoms due to improper technique and repetitive movements. Although Mike Melgoza works out of town, he visits Dr. Alex Jimenez every time he begins to experience pain to receive chiropractic care. Mike Melgoza recommends Dr. Alex Jimenez as the non-surgical choice for chronic pain. Mike Melgoza trusts Dr. Jimenez to care for his health.
Doctor Of Chiropractic Near Me
Before you go to a chiropractor to deal with your chronic pain symptoms, it’s important to understand what exactly is causing your pain. Your physician will perform a physical exam as well as some tests to help them diagnose the source of the patient’s pain. As soon as you’re diagnosed with a pain illness, your chiropractor will create a treatment program. Your treatment plan may include spinal manipulation, manual therapies, and therapeutic exercises. Work with your chiropractor to develop a treatment plan. Once your pain is fully addressed, you should be able to slowly resume daily activities.
We are blessed to present to you�El Paso�s Premier Wellness & Injury Care Clinic.
As El Paso�s Chiropractic Rehabilitation Clinic & Integrated Medicine Center,�we passionately are focused treating patients after frustrating injuries and chronic pain syndromes. We focus on improving your ability through flexibility, mobility and agility programs tailored for all age groups and disabilities.
If you have enjoyed this video and/or we have helped you in any way please feel free to subscribe and share us.
Chiropractor Near Me: Due to his previous back injury history, George Lara suffered a recent back injury which he was unfortunately unable to recover from through traditional treatment. That’s when the VA recommended him to seek chiropractic care with Dr. Alex Jimenez, ultimately changing his quality of life. George Lara had degenerative disc disease, or DDD, and sciatic nerve pain before receiving treatment with Dr. Alex Jimenez. George Lara describes how much his life has improved with chiropractic care and he’s grateful of the services and care he received. George Lara recommends Dr. Alex Jimenez as the non-surgical choice for back pain, among other spine health issues.
Chiropractor Near Me
Chiropractic care is a means to diagnose and treat health problems that affect the nerves, muscles, bones, and joints of the body. A healthcare provider who supplies chiropractic care is known as a chiropractor. Adjustment of the spine, known as manipulation, is the basis of care. Chiropractors also use other kinds of treatments. Your physician will ask about your goals for your health history and therapy. It’s important to inform your physician about any physical problems you may have which make it difficult for you to do particular things.
We are blessed to present to you�El Paso�s Premier Wellness & Injury Care Clinic.
As El Paso�s Chiropractic Rehabilitation Clinic & Integrated Medicine Center,�we passionately are focused treating patients after frustrating injuries and chronic pain syndromes. We focus on improving your ability through flexibility, mobility and agility programs tailored for all age groups and disabilities.
If you have enjoyed this video and/or we have helped you in any way please feel free to subscribe and share us.
IFM's Find A Practitioner tool is the largest referral network in Functional Medicine, created to help patients locate Functional Medicine practitioners anywhere in the world. IFM Certified Practitioners are listed first in the search results, given their extensive education in Functional Medicine
Abstract
